A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test
This study aimed to investigate whether changes in progastrin-releasing peptide (ProGRP) levels correlate with treatment response and can be used to optimize clinical management of patients with small-cell lung cancer. Patients with small-cell lung cancer (any stage) receiving chemotherapy were elig...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-09-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428320958603 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850044824825102336 |
|---|---|
| author | Thomas Muley Xiaotong Zhang Stefan Holdenrieder Catharina M Korse Xiu-yi Zhi Rafael Molina Zhongjuan Liu Gunther Hartmann Michel M van den Heuvel Kun Qian Ramon Marrades Christine Engel Ying He Birgit Wehnl Farshid Dayyani Felix Herth |
| author_facet | Thomas Muley Xiaotong Zhang Stefan Holdenrieder Catharina M Korse Xiu-yi Zhi Rafael Molina Zhongjuan Liu Gunther Hartmann Michel M van den Heuvel Kun Qian Ramon Marrades Christine Engel Ying He Birgit Wehnl Farshid Dayyani Felix Herth |
| author_sort | Thomas Muley |
| collection | DOAJ |
| description | This study aimed to investigate whether changes in progastrin-releasing peptide (ProGRP) levels correlate with treatment response and can be used to optimize clinical management of patients with small-cell lung cancer. Patients with small-cell lung cancer (any stage) receiving chemotherapy were eligible. ProGRP was measured in serum/plasma at baseline and after each chemotherapy cycle using the Elecsys ® ProGRP assay (Roche Diagnostics). Treatment response was assessed by computed tomography scan. The primary objective was to examine whether changes in ProGRP levels correlated with computed tomography scan results after two cycles of chemotherapy. The prognostic value of ProGRP among patients receiving first-line chemotherapy was also assessed. Overall, 261 patients from six centers were eligible. Among patients with elevated baseline ProGRP (>100 pg/mL), a ProGRP decline after Cycle 2 was associated with nonprogression (area under the curve: 84%; 95% confidence interval: 72.8–95.1; n = 141). ProGRP changes from baseline to end of Cycle 1 were predictive of response, as determined by computed tomography scan 3 weeks later (area under the curve: 87%; 95% confidence interval: 74.1−99.2; n = 137). This was enhanced by repeat measurements, with a 92% area under the curve (95% confidence interval: 85.3−97.8) among patients with ProGRP data after both Cycles 1 and 2 (n = 123); if a patient experienced a ≥25% decline in ProGRP after Cycle 1, and ProGRP remained stable or decreased after Cycle 2, the probability of finding progression on the interim computed tomography scan at the end of Cycle 2 was almost zero (sensitivity: 100%, specificity: 71%). Both ProGRP levels at baseline and at the end of first-line chemotherapy were prognostic; the latter provided a moderately improved hazard ratio of 2.43 (95% confidence interval: 1.33–4.46; n = 110) versus 1.87 (95% confidence interval: 1.04–3.37; n = 216). In summary, for patients with small-cell lung cancer and elevated baseline ProGRP levels, ProGRP may be a simple, reliable, and repeatable tool for monitoring response to chemotherapy and provide valuable prognostic information. |
| format | Article |
| id | doaj-art-de453d033ca24de7ad50985f43964c44 |
| institution | DOAJ |
| issn | 1423-0380 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-de453d033ca24de7ad50985f43964c442025-08-20T02:54:50ZengSAGE PublishingTumor Biology1423-03802020-09-014210.1177/1010428320958603A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood testThomas Muley0Xiaotong Zhang1Stefan Holdenrieder2Catharina M Korse3Xiu-yi Zhi4Rafael Molina5Zhongjuan Liu6Gunther Hartmann7Michel M van den Heuvel8Kun Qian9Ramon Marrades10Christine Engel11Ying He12Birgit Wehnl13Farshid Dayyani14Felix Herth15Translational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL), Heidelberg, GermanyPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaUniversity Hospital Bonn, Bonn, GermanyThe Netherlands Cancer Institute, Amsterdam, The NetherlandsXuanwu Hospital, Capital Medical University, Beijing, ChinaHospital Clinic, University of Barcelona, Barcelona, SpainPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaUniversity Hospital Bonn, Bonn, GermanyRadboud University Medical Center, Nijmegen, The NetherlandsXuanwu Hospital, Capital Medical University, Beijing, ChinaHospital Clinic, University of Barcelona, Barcelona, SpainRoche Diagnostics GmbH, Penzberg, GermanyRoche Diagnostics GmbH, Penzberg, GermanyRoche Diagnostics GmbH, Penzberg, GermanyUniversity of California, Irvine, Irvine, CA, USATranslational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL), Heidelberg, GermanyThis study aimed to investigate whether changes in progastrin-releasing peptide (ProGRP) levels correlate with treatment response and can be used to optimize clinical management of patients with small-cell lung cancer. Patients with small-cell lung cancer (any stage) receiving chemotherapy were eligible. ProGRP was measured in serum/plasma at baseline and after each chemotherapy cycle using the Elecsys ® ProGRP assay (Roche Diagnostics). Treatment response was assessed by computed tomography scan. The primary objective was to examine whether changes in ProGRP levels correlated with computed tomography scan results after two cycles of chemotherapy. The prognostic value of ProGRP among patients receiving first-line chemotherapy was also assessed. Overall, 261 patients from six centers were eligible. Among patients with elevated baseline ProGRP (>100 pg/mL), a ProGRP decline after Cycle 2 was associated with nonprogression (area under the curve: 84%; 95% confidence interval: 72.8–95.1; n = 141). ProGRP changes from baseline to end of Cycle 1 were predictive of response, as determined by computed tomography scan 3 weeks later (area under the curve: 87%; 95% confidence interval: 74.1−99.2; n = 137). This was enhanced by repeat measurements, with a 92% area under the curve (95% confidence interval: 85.3−97.8) among patients with ProGRP data after both Cycles 1 and 2 (n = 123); if a patient experienced a ≥25% decline in ProGRP after Cycle 1, and ProGRP remained stable or decreased after Cycle 2, the probability of finding progression on the interim computed tomography scan at the end of Cycle 2 was almost zero (sensitivity: 100%, specificity: 71%). Both ProGRP levels at baseline and at the end of first-line chemotherapy were prognostic; the latter provided a moderately improved hazard ratio of 2.43 (95% confidence interval: 1.33–4.46; n = 110) versus 1.87 (95% confidence interval: 1.04–3.37; n = 216). In summary, for patients with small-cell lung cancer and elevated baseline ProGRP levels, ProGRP may be a simple, reliable, and repeatable tool for monitoring response to chemotherapy and provide valuable prognostic information.https://doi.org/10.1177/1010428320958603 |
| spellingShingle | Thomas Muley Xiaotong Zhang Stefan Holdenrieder Catharina M Korse Xiu-yi Zhi Rafael Molina Zhongjuan Liu Gunther Hartmann Michel M van den Heuvel Kun Qian Ramon Marrades Christine Engel Ying He Birgit Wehnl Farshid Dayyani Felix Herth A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test Tumor Biology |
| title | A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test |
| title_full | A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test |
| title_fullStr | A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test |
| title_full_unstemmed | A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test |
| title_short | A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test |
| title_sort | continuous responder algorithm to optimize clinical management of small cell lung cancer with progastrin releasing peptide as a simple blood test |
| url | https://doi.org/10.1177/1010428320958603 |
| work_keys_str_mv | AT thomasmuley acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT xiaotongzhang acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT stefanholdenrieder acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT catharinamkorse acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT xiuyizhi acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT rafaelmolina acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT zhongjuanliu acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT guntherhartmann acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT michelmvandenheuvel acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT kunqian acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT ramonmarrades acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT christineengel acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT yinghe acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT birgitwehnl acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT farshiddayyani acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT felixherth acontinuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT thomasmuley continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT xiaotongzhang continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT stefanholdenrieder continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT catharinamkorse continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT xiuyizhi continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT rafaelmolina continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT zhongjuanliu continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT guntherhartmann continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT michelmvandenheuvel continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT kunqian continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT ramonmarrades continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT christineengel continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT yinghe continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT birgitwehnl continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT farshiddayyani continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest AT felixherth continuousresponderalgorithmtooptimizeclinicalmanagementofsmallcelllungcancerwithprogastrinreleasingpeptideasasimplebloodtest |